Psychostimulants

Journal of Pain and Symptom Management

Volumn 40, Issue 5, 2010, Pages 789-795

  Howard, Paul ^a   Shuster, John ^b   Twycross, Robert ^c   Mihalyo, Mary ^d   Wilcock, Andrew ^e  

^a Duchess of Kent House   (United Kingdom)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DUQUESNE UNIVERSITY   (United States)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ARMODAFINIL; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DIAZEPAM; HORMONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISDEXAMFETAMINE; METHYLPHENIDATE; MIDAZOLAM; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PHENYTOIN; PROCARBAZINE; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ADDICTION; AGITATION; ANGINA PECTORIS; ANOREXIA; ANXIETY; BRAIN VASCULITIS; CARDIOVASCULAR DISEASE; CLOSED ANGLE GLAUCOMA; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG INDICATION; DRUG RESEARCH; EPILEPSY; HEADACHE; HEART ARRHYTHMIA; HOSPICE CARE; HUMAN; HYPERPYREXIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPERTHYROIDISM; INSOMNIA; MENTAL DISEASE; MORNING DOSAGE; MOTOR DYSFUNCTION; PALLIATIVE THERAPY; PSYCHOSIS; RASH; REVIEW; SEIZURE THRESHOLD; SIDE EFFECT; SKIN MANIFESTATION; TACHYCARDIA;

EID: 78349240020     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.09.004     Document Type: Short Survey

References (38)

1. R. Kumar Approved and investigational uses of modafinil: an evidence-based review Drugs 68 2008 1803 1839
2. B. Boutrel, and G.F. Koob What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications Sleep 27 2004 1181 1194
3. W.M. Qu, Z.L. Huang, X.H. Xu, N. Matsumoto, and Y. Urade Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil J Neurosci 28 2008 8462 8469
4. N.D. Volkow, J.S. Fowler, and J. Logan Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications JAMA 301 2009 1148 1154
5. M. Candy, L. Jones, R. Williams, A. Tookman, and M. King Psychostimulants for depression Cochrane Database Syst Rev 2 2008 CD006722
6. A.E. Fleckenstein, T.J. Volz, E.L. Riddle, J.W. Gibb, and G.R. Hanson New insights into the mechanism of action of amphetamines Annu Rev Pharmacol Toxicol 47 2007 681 698
7. D. Sulzer, M.S. Sonders, N.W. Poulsen, and A. Galli Mechanisms of neurotransmitter release by amphetamines: a review Prog Neurobiol 75 6 2005 406 433
8. S. Kapur, R. Mizrahi, and M. Li From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis Schizophr Res 79 1 2005 59 68
9. N.D. Volkow, G.J. Wang, J.S. Fowler, and Y.S. Ding Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder Biol Psychiatry 57 11 2005 1410 1415
10. S. Dein, and R. George A place for psychostimulants in palliative care? J Palliat Care 18 2002 196 199
11. P.S. Masand, and G.E. Tesar Use of stimulants in the medically ill Psychiatr Clin North Am 19 3 1996 515 547
12. M.M. Burns, and S.J. Eisendrath Dextroamphetamine treatment for depression in terminally ill patients Psychosomatics 35 1994 80 83
13. T.D. Challman, and J.J. Lipsky Methylphenidate: its pharmacology and uses Mayo Clin Proc 75 2000 711 721
14. R. de la Torre, M. Farré, and M. Navarro Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices Clin Pharmacokinet 43 3 2004 157 185
15. D.F. Connor, and R.J. Steingard New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential CNS Drugs 18 2004 1011 1030
16. P. Robertson Jr., and E.T. Hellriegel Clinical pharmacokinetic profile of modafinil Clin Pharmacokinet 42 2003 123 137
17. S. Block Assessing and managing depression in the terminally ill patient Ann Intern Med 132 2000 209 218
18. K. Orr, and D. Taylor Psychostimulants in the treatment of depression: a review of the evidence CNS Drugs 21 2007 239 257
19. L. Radbruch, F. Strasser, and F. Elsner Fatigue in palliative care patients - an EAPC approach Palliat Med 22 2008 13 32
20. O. Minton, A. Richardson, M. Sharpe, M. Hotopf, and P. Stone A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue J Natl Cancer Inst 100 16 2008 1155 1166
21. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology: cancer-related fatigue Available from http://www.nccn.org/professionals/physician-gls/PDF/fatigue.pdf Accessed October 5, 2010
22. E. Bruera, V. Valero, and L. Driver Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial J Clin Oncol 24 2006 2073 2078
23. K.A. Auret, S.A. Schug, A.P. Bremner, and M. Bulsara A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer J Pain Symptom Manage 37 2009 613 621
24. H.G. Mar Fan, M. Clemons, and W. Xu A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer Support Care Cancer 16 2008 577 583
25. E.E. Lower, S. Fleishman, and A. Cooper Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial J Pain Symptom Manage 38 2009 650 662
26. L.E. Lundorff, B.H. Jønsson, and P. Sjøgren Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial Palliat Med 23 2009 731 738
27. J.S. Lou, D.M. Dimitrova, and B.S. Park Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study Clin Neuropharmacol 32 2009 305 310
28. R. Lange, M. Volkmer, C. Heesen, and J. Liepert Modafinil effects in multiple sclerosis patients with fatigue J Neurol 256 2009 645 650
29. B. Stankoff, E. Waubant, and C. Confavreux Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study Neurology 64 2005 1139 1143
30. J.G. Rabkin, P.H. Gordon, and M. McElhiney Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study Muscle Nerve 39 2009 297 303
31. K.W. Rammohan, and D.J. Lynn Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study Neurology 65 2005 1995 1997 author reply 1995-1997
32. R. Twycross, and A. Wilcock Adjuvant analgesics R. Twycross, A. Wilcock, Hospice and palliative care formulary USA 2nd ed. 2008 palliativedrugs.com Nottingham 222 227
33. R. Twycross, and A. Wilcock Opioid dose conversion ratios R. Twycross, A. Wilcock, Hospice and palliative care formulary USA 2nd ed. 2008 palliativedrugs.com Nottingham 485 490
34. S. Dalal, and R. Melzack Potentiation of opioid analgesia by psychostimulant drugs: a review J Pain Symptom Manage 16 1998 245 253 (Pubitemid 28478238)
35. E. Bruera, C. Brenneis, A.H. Paterson, and R.N. MacDonald Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer J Pain Symptom Manage 4 1989 3 6 (Pubitemid 19093472)
36. M.B. Wilwerding, C.L. Loprinzi, and J.A. Mailliard A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics Support Care Cancer 3 1995 135 138
37. E. Bruera, R. Fainsinger, T. MacEachern, and J. Hanson The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report Pain 50 1992 75 77
38. E. Bruera, M.J. Miller, K. Macmillan, and N. Kuehn Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain Pain 48 1992 163 166